AxoGen is a biotech company developing treatment options for the reconstruction and repair of peripheral nerve injuries. It is passionate about restoring nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body.
AxoGen's portfolio of products includes Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves, AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a soft tissue covering to reduce inflammation and scar tissue formation. 

Alachua, US
Size (employees)
114 (est)+41%
AxoGen was founded in 2002 and is headquartered in Alachua, US

Key People/Management at AxoGen

Karen Zaderej

Karen Zaderej

Gregory G. Freitag

Gregory G. Freitag

General Counsel, SVP Business Development, Director

AxoGen Office Locations

AxoGen has offices in Alachua and Burleson
Alachua, US (HQ)
13631 Progress Blvd
Burleson, US
300 Boone Rd
Show all (2)

AxoGen Financials and Metrics

AxoGen Financials

AxoGen's revenue was reported to be $41.1 m in FY, 2016

Revenue (Q3, 2017)

16 m

Gross profit (Q3, 2017)

13.5 m

Gross profit margin (Q3, 2017), %


Net income (Q3, 2017)

(2.1 m)

EBIT (Q3, 2017)

(1.5 m)

Market capitalization (22-Dec-2017)

128.2 m

Cash (30-Sep-2017)

22 m
AxoGen's current market capitalization is $128.2 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


10.9 m16.8 m27.3 m41.1 m

Revenue growth, %


Cost of goods sold

2.4 m3.4 m4.8 m6.5 m

Gross profit

8.5 m13.4 m22.5 m34.6 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


3 m3.1 m4.2 m4.7 m5 m6.4 m8.2 m8.1 m10.4 m11.2 m12.2 m15.2 m16 m

Cost of goods sold

650.2 k701.3 k887.8 k896.2 k982.9 k1 m1.4 m1.4 m1.5 m1.7 m1.9 m2.3 m2.5 m

Gross profit

2.3 m2.4 m3.3 m3.8 m4 m5.4 m6.7 m6.7 m8.8 m9.5 m10.3 m12.9 m13.5 m

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


20.1 m8.2 m25.9 m30 m

Accounts Receivable

1.2 b


3.4 m3.2 m3.9 m5.5 m

Current Assets

25.7 m14.4 m35.1 m44 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


22.6 m16.8 m14.2 m11.8 m19.3 m15.6 m29.9 m20.9 m18.3 m16 m25.9 m23.9 m22 m

Accounts Receivable

1.7 m


3.5 m3.5 m3.4 m3.3 m3.3 m3.5 m3.7 m4.5 m4.8 m5 m5.9 m6.3 m6.7 m

Current Assets

28 m22.4 m20.3 m18 m26 m23.2 m38.6 m31.5 m29.7 m28.7 m40.9 m40.2 m39.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(14.6 m)(17.7 m)(13.4 m)(14.4 m)

Depreciation and Amortization

138.3 k198.9 k249 k

Accounts Receivable

(902.2 k)(1 m)(2 m)


(247.3 k)184.8 k(720.3 k)5.5 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(3.6 m)(4.2 m)(3.7 m)(3.2 m)(3.6 m)(3.2 m)(3 m)(3.7 m)(2.8 m)(2.3 m)(3.8 m)


3.4 m3.3 m3.3 m3.5 m3.7 m4.5 m4.8 m5 m5.9 m

Accounts Payable

2.2 m2 m3.4 m3.4 m4.1 m3.8 m3.9 m4.6 m6.7 m
Y, 2017

Financial Leverage

4 x
Show all financial metrics

AxoGen Market Value History

AxoGen's Web-traffic and Trends

AxoGen Online and Social Media Presence

AxoGen Company Life and Culture

You may also be interested in